Simplifying rare disease management
At Audaire Health, our mission is to improve patient care and support optimal management of high-cost drug therapies.
Hemophilia Management Service
It is estimated that 25% of healthcare spend is attributed to waste. With rare diseases like hemophilia, that number represents a $1.5 billion opportunity for healthcare payers in the US.
It is imperative that hemophilia factor products be prescribed with evidence-based guidelines and pharmacies be monitored for optimal dispensing patterns.
Audaire Health’s Hemophilia Management service provides payers with full transparency on physician, pharmacy and patient performance providing payers immediate ROI.
Gene Therapy Management Service
With an estimated 60 gene therapies to be approved in the next ten years, the cost to the healthcare system could be as high as $100B! Gene therapies will be very expensive and administering outcomes-based agreements will be costly and time-consuming.
With each new gene therapy, payers will have another unique set of outcomes to capture & contract requirements to meet, and with this complexity, the administration burden becomes even higher.
Audaire Health’s new Gene Therapy Management service is built to ensure payers get the maximum value from these novel therapies.
Want to stay up-to-date on the latest from Audaire Health? Sign up here: